Listed

Opus Genetics, Inc.: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 3, 2017 and accepted by EDGAR at Nov 3, 2017, 16:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-07-01 to 2017-09-30$2.6mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-01-01 to 2017-09-30$7.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-07-01 to 2017-09-30−$4.2mus-gaap:OperatingIncomeLoss
Operating income9 months2017-01-01 to 2017-09-30−$12.5mus-gaap:OperatingIncomeLoss
Net income3 months2017-07-01 to 2017-09-30−$1.0mus-gaap:NetIncomeLoss
Net income9 months2017-01-01 to 2017-09-30−$21.7mus-gaap:NetIncomeLoss
Diluted EPS9 months2017-01-01 to 2017-09-30−$0.83us-gaap:EarningsPerShareBasicAndDiluted
Cash and equivalentsAt period end2017-09-30$8.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-09-30$24.5mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$24.6mus-gaap:Assets
Total liabilitiesAt period end2017-09-30$9.5mus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30$15.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001140361-17-040967. Last ingested by Listed: Nov 12, 2026, 19:22 ET. Listed shows no prices and gives no investment advice.